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Abstract 
A Trojan-horse strategy for cancer therapy employing tumor-tropic mesenchymal stem cells 
transfected with a non-viral nanovector is here presented. In this sense, ultrasound-responsive 
mesoporous silica nanoparticles were coated with a polycation (using two different molecular 
weights), providing them with gene transfection capabilities that were evaluated using two 
different plasmids. First, the expression of Green Fluorescent Protein was analyzed in Decidua-
derived Mesenchymal Stem Cells after incubation with the silica nanoparticles. The most 
successful nanoparticle was then employed to induce the expression of two suicide genes: 
cytosine deaminase and uracil phosphoribosyl transferase, which allow the cells to convert a 
non-toxic pro-drug (5-fluorocytosine) into a toxic drug (5-Fluorouridine monophosphate). The 
effect of the production of the toxic final product was also evaluated in a cancer cell line (NMU 
cells) co-cultured with the transfected vehicle cells, Decidua-derived Mesenchymal Stem Cells. 
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Cell-based cancer therapies have attracted great attention with many different cell types being 
proposed due to their tumor-tropic behavior [1–5]. Mesenchymal Stem Cells (MSCs) have been 
extensively evaluated for cancer therapy [5] because of their inherent tumor-suppressing 
capacities [6,7], as well as by their capacity to be transfected with therapeutic genes [8,9],  or 
by acting as carriers of nanodrugs [3,10]. 
Regarding therapeutic approaches involving gene transfection, a promising strategy consists in 
inducing the expression of a suicide gene [11]. Suicide genes can act either directly, encoding 
a protein that is toxic, or indirectly, encoding an enzyme that can lead to the production of a 
toxic molecule [11]. Tumor-tropic cells transfected with suicide genes can induce cell death of  
both, the transfected vehicle cell and the surrounding cancer cells [8,9,12,13], in a phenomenon 
known as the “bystander effect” [14]. However, most of these approaches have relied on viral 
vectors as transfection agents, which present several safety concerns regarding their clinical 
application [8,15,16]. Then, gene transfection using non-viral vectors might be more suitable 
for developing therapeutic strategies [12].  
Likewise, a particularly interesting type of MSCs are Decidua-derived Mesenchymal Stem 
Cells (DMSCs) obtained from human placenta [17], which have been shown to inhibit tumor 
progression [6]. We have recently reported the use of DMSCs as vehicles capable of 
transporting Mesoporous Silica Nanoparticles (NPs) and Ultrasound-responsive NPs (UR-
NPs) towards tumors, both in vitro [17]and in vivo [18]. These UR-NPs can be loaded with 
doxorubicin (a cytotoxic drug) and then, upon ultrasound exposure, the drug is released killing 
surrounding cancer cells [17].  
The objective of the present work is to use engineered UR-NPs as non-viral transfection agents 
of a suicide gene to transform DMSCs into a Trojan-horse for cancer therapy. DMSCs will 




toxic pro-drug, will generate highly toxic species capable of killing the surrounding cancer 
cells. Moreover, a critical advantage of using a stimulus-responsive nanocarrier, such as UR-
NPs, is that it could enable a combined strategy in which both, small therapeutic molecules, 
like doxorubicin, and a plasmid, are delivered to the vehicle cells. In this combined strategy, 
DMSCs would uptake nanoparticles carrying both, an anticancer drug and a plasmid encoding 
suicide genes for further systemic injection. After migration towards tumor tissue, a therapeutic 
effect will be produced by the conversion of an injected non-toxic pro-drug into toxic species. 
Afterwards, another therapeutic effect will happen upon application of ultrasound in the area 
of interest, which would induce the release of the anticancer drug. This approach could 
drastically improve the therapeutic outcome by exploiting synergisms between both 
mechanisms of action [19]. The non-toxic nature of the employed pro-drug and the avoidance 
of premature release of the anticancer drug by UR-NPs would significantly reduce undesired 
side effects of anticancer treatments. 
2. Materials and methods  
2.1 Synthesis and evaluation of polycation-coated UR-NPs 
Synthesis of UR-NPs: Ultrasound-responsive Mesoporous Silica Nanoparticles were obtained 
as described elsewhere [20], by grafting the polymeric gate poly-(2-(2-methoxyethoxy)ethyl 
methacrylate-co-2-tetrahydropyranyl methacrylate), p(MEO2MA-co-THPMA), to mesoporous 
silica nanoparticles. Those MCM-41 type mesoporous silica nanoparticles were prepared 
following a modified Stöber method, based on the condensation of Tetraethyl orthosilicate 
under dilute conditions in the presence of Hexadecyltrimethylammonium bromide [20]. The 
surfactant was removed by ionic exchange with NH4NO3 and the particles were collected by 
centrifugation and washed with ethanol [18,20]. The ultrasound-responsive copolymer 
p(MEO2MA-co-THPMA) was obtained by Free Radical Polymerization of MEO2MA and 




grafted on the surface of Mesoporous Silica Nanoparticles by conjugating it with 3-
Aminopropyltriethoxysilane (APTES) through dicyclohexylcarbodiimide/N-
Hydroxysuccinimide (DCC/NHS) chemistry, and then through the condensation of the APTES 
moieties on the silica surface [17,20].  
Polyethylenimine (PEI) coating of UR-NPs: UR-NPs were coated with linear PEI of two 
molecular weights (1.8 kDa or 5 kDa), obtaining UR-NPs@1.8PEI and UR-NPs@5PEI, 
respectively. UR-NPs@PEI were obtained by dissolving 5 mg of PEI (1.8 or 5 kDa) in 0.5mL 
of deionized (DI) water with 3 µL of acetic acid (glacial). The PEI solution was then diluted 
with 0.5mL of 10 mM Phosphate-buffered saline (PBS) solution. That PEI solution was then 
added to 10 mg of UR-NPs dispersed in PBS (final volume of 2 mL). The coating was carried 
out at 37 ºC for 3 h under orbital stirring. The product was then washed several times with PBS, 
centrifuged and dried under vacuum at room temperature. 
The nanoparticles here obtained were characterized by different techniques. Z potential and 
Dynamic Light Scattering (DLS) measurements were performed in DI water by means of a 
Zetasizer Nano ZS (Malvern Instruments) equipped with a 633 nm “red” laser. Fourier 
Transformed Infrared (FTIR) spectra were obtained in a Nicolet (Thermo Fisher Scientific) 
Nexus spectrometer equipped with a Smart Golden Gate ATR accessory. Transmission 
Electron Microscopy (TEM) was carried out with a JEOL JEM 2100 instrument operated at 
200 kV, equipped with a CCD camera (KeenView Camera). Phosphotungstic acid staining was 
employed to detect the presence of organic matter in the obtained materials. Small Angle X-
ray diffraction (SAXRD) was performed in a Philips X-Pert MPD diffractometer equipped with 
Cu Kα radiation. 
Cargo loading and release: The Lower Critical Solution Temperature (LCST) behaviour of 
this system [20] was exploited to load a cargo in the mesopores. UR-NPs (20 mg) were placed 




suspension was stirred for 24 h. The sample was then filtered and washed twice with pre-heated 
PBS (50 °C) to remove non-loaded fluorescein. The loaded UR-NPs were then coated with PEI 
as described above. 
For the release experiments, a suspension of 5 mg/mL fluorescein-loaded nanoparticles was 
prepared in 10 mM PBS pH=7.4. UR-NPs suspension was exposed to ultrasound (10 min at 
1.3 MHz and 100 W in a commercial laboratory ultrasound apparatus [20]). The samples were 
then incubated at 37 ºC under orbital shaking for 2 h. The particles were collected by 
centrifugation and the amount of fluorescein released was evaluated by fluorescence 
spectrometry (λexc 490, λem 510-590 nm). Control experiments without ultrasound were 
performed in parallel. 
2.2 Isolation and culture of DMSCs 
Human placentas were obtained from the Department of Obstetrics and Gynecology under 
written informed consent approved by the Ethics Committee from Hospital Universitario 12 
de Octubre. Processing of placental membranes and culture of primary cells was done as 
previously described [21]. Extra-embryonic membranes were processed by enzymatic 
digestion with trypsin–EDTA (Lonza, Spain). Isolated cells were grown in complete culture 
medium consisting of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 
mM of glutamine, 0.1 mM of sodium pyruvate, 55 mM β-mercaptoethanol, 1% non-essential 
amino acids, 1% penicillin/ streptomycin, 10% fetal bovine serum and 10 ng/mL of EGF 
(epidermal growth factor), at 37 ºC, 5% CO2 and 95% humidity. Non-adherent cells were 
discarded after 5 days. At confluence, adherent cells were passaged and seeded at a density of 
104 cells per cm2. 




Plasmid binding: Two plasmids were used: a plasmid encoding Green Fluorescence Protein 
(GFP) and a plasmid containing a suicide fusion gene consisting of the sequences for cytosine 
deaminase (CD) and uracil phosphoribosyl transferase (UPRT). This CD:UPRT plasmid 
(pSELECT-zeo-Fcy::fur) was purchased from InvivoGen (USA). For transfection, 7.5 µg of 
plasmid were mixed with 1 mg of UR-NPs@PEI in 1 mL of Dulbecco's Modified Eagle's 
Medium (DMEM), stirred at room temperature for 15 min, and then incubated in 5 mL final 
volume with DMSCs for 2 h at 37 ºC. The transfected cells were washed with PBS twice to 
remove non-internalized nanoparticles and incubated in complete culture medium.  
Transfection of GFP: Expression of GFP was evaluated by fluorescence microscopy and flow 
cytometry 72 hours after transfection. Fluorescence microscopy was performed with an EVOS 
FL Cell Imaging System from AMG (Advance Microscopy Group). Flow cytometry was 
performed in a BD FACSCalibur™ cytometer (Beckton Dickinson), and data processed by 
Flowing Software.  
Transfection of CD:UPRT: Expression of CD:UPRT was evaluated by DMSCs viability, 
reverse transcription polymerase chain reaction (RT-PCR) and 5-fluorocytosine (5-FC) 
conversion in vial.  
DMSCs viability was assessed after exposure to 0.05 mg/mL of 5-FC by flow cytometry. Flow 
cytometry was performed using apoptosis/necrosis staining kit (BD PharmingenTM FITC 
Annexin V Apoptosis Detection Kit I) following the manufacturer instructions. 
In addition, expression of transfected CD:UPRT plasmid was assessed by RT-PCR. Total RNA 
was recovered from silica membrane columns of NZY Total RNA Isolation kit (NZYtech) after 
DNAse I digestion. One microgram of RNA was used for reverse transcription using High 
Capacity cDNA Reverse Transcription kit (Applied Biosystem).  Complementary DNA 




construction (A), and human β-actin (B) as control (Table S1). PCR reactions were resolved in 
2 % agarose gel and visualized by SYBR green staining. 
Furthermore, expression of CD:UPRT plasmid was evaluated by 5-FC conversion in vial. CD 
enzyme activity was measured by UV-Vis spectrophotometry with a HELIOS-ZETA UV-vis 
spectrophotometer [15]. DMSCs (105 cells/experiment) were resuspended in 70 µL PBS and 
lysed by freeze-thawing. Lysates were centrifuged at 15000 rpm for 20 min at 4 ºC and 50 µL 
of supernatant were mixed with 50 µL of 0.4 mg/mL 5-FC in PBS and incubated at 37 ºC for 
0 and 16 h. Then, 40 µL were quenched with 360 µL of 0.1M HCl and absorbance was 
measured at 255 and 290 nm. Enzymatic conversion of 5-FC was calculated as described [15]. 
2.4 Co-culture of transfected Trojan-horse platform with NMU cancer cells. 
DMSCs transfected with CD:UPRT-loaded UR-NPs@5PEI were co-cultured with NMU rat 
mammary cancer cells (ATCC, LGC Standards S.L.U.) [17,18]. NMU cells were cultured in 
24 well plates at a density of 20,000 cells per well. After 24 h, DMSCs (with or without 
nanoparticles) were seeded in Transwell® culture inserts (0.4 µm pore, polycarbonate 
membranes, tissue cultured treated, Costar®) in a ratio 1:2 (DMSC:NMU). After 72 hours, 5-
FC was added to the medium at 0.1 mg/mL. Four days later, the inserts were removed and the 
viability of NMU cells was evaluated by Alamar Blue assay following the manufacturer’s 
instructions. NMU cells were also analyzed by flow cytometry with BD PharmingenTM FITC 
Annexin V Apoptosis Detection Kit I.  
Statistical analyses were performed by the Student’s t test. 
3. Results and Discussion 
Ultrasound-responsive mesoporous silica nanoparticles were engineered to include nucleic 
acids into a polycationic coating to provide gene transfection capacities. The successful 




characterization techniques. The prepared nanoparticles showed round-shape morphology and 
a diameter around 200 nm, as observed in the TEM micrographs (Figure 1a). The presence of 
the polymeric ultrasound-responsive gates and the successful coating with two different 
molecular weights of PEI was confirmed by TEM micrographs (FigureS1a, organic matter 
showing darker contrast by staining with phosphotungstic acid), and by FTIR spectra (Figure 
S1b, bands in the range 1300-1800 cm-1). TEM micrographs also showed that the ordered 
porosity of the materials had been maintained throughout their preparation. Additionally, the 
preservation of the mesopore order (typical of MCM-41 type materials) could be observed in 
all prepared materials in the corresponding SAXRD patterns (Figure S1c). Successful coating 
of UR-NPs with both types of PEI was confirmed by the change to positive values in the zeta 
potential (Figure 1b). This positively-charged polymeric coating will enable the binding of 
negatively-charged plasmids to be used in gene transfection. Nanoparticle size measurements 
carried out by DLS show a hydrodynamic diameter of ca. 340 nm for UR-NPs@PEI, which 
then increased to ca. 530 nm after DNA complexation (Figure S2). It is worth mentioning that 
our nanoparticles (and their complexes with nucleic acids) will not be in direct contact with the 
circulatory system, since the nanoparticles will already be inside vehicle cells and non-
internalized nanoparticles will be removed before injection. 
To test the transfection potential of UR-NPs@1.8PEI and UR-NPs@5PEI, the GFP-expressing 
plasmid was used. Figure 2 shows that no significant gene expression was achieved with 1.8 
kDa PEI-coated NPs. On the other hand, DMSCs transfected with UR-NPs@5PEI expressed 
GFP, as can be observed by fluorescence microscopy and flow cytometry. These results are in 
good agreement with previous literature showing that gene transfection efficiency of PEI is 
directly related to its molecular weight [22]. However, the toxicity of PEI is also related to its 
molecular weight [22], and when a 25 kDa PEI was used, the vast majority of DMSCs were 
substantially damaged (data not shown). Therefore, the 5 kDa PEI was chosen for all further 




GFP expression was maintained in transfected DMSCs up to 14 days as was observed by 
fluorescence microscopy (data not shown), suggesting that gene expression would be continued 
after DMSCs migration to tumor [6,18]. 
Previous data showed that 1.8 kDa PEI coating did not affect the nanoparticle capacity of 
releasing a cargo upon ultrasound exposure [17]. However, we did not know whether a larger 
polycationic coating could hamper the correct performance of our nanodevice. To assess 
whether the ultrasound-responsiveness was maintained after 5 KDa PEI coating, an in vial 
cargo release experiment using fluorescein was performed (Figure 3). Fluorescence intensity 
in the supernatant of the samples exposed to ultrasound was highly increased compared to 
samples without insonation, indicating that the 5 kDa PEI coating does not prevent the opening 
of the polymeric gate in response to the stimulus. Upon ultrasound exposure, the monomer 
THPMA in the polymeric coating, p(MEO2MA-co-THPMA), is converted into a much more 
hydrophilic monomer (methacrylic acid). This change modifies the overall hydrophilicity of 
the system and induces a conformational change of the polymeric gate, exposing the 
nanoparticle pores to the environment and enabling cargo release. These results confirm the 
on-demand cargo release capabilities of UR-NPs@5PEI, which would enable them to carry a 
toxic drug preventing its premature release, which might compromise the viability of the 
vehicle DMSCs. 
The next step after optimizing the conditions for gene transfection using UR-NPs@5PEI 
consisted in the use of a plasmid of therapeutic interest to be transfected in the vehicle DMSCs, 
to obtain our Trojan-horse platform. A plasmid containing two genes involved in suicide gene 
therapy, cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT), was used. CD 
converts non-toxic pro-drug 5-fluorocytosine (5-FC) into toxic 5-Fluoruracil (5-FU), which is 
then further transformed by UPRT into the more toxic 5-Fluorouridine monophosphate (5-




The plasmid containing the suicide genes (CD:UPRT plasmid) was loaded into the UR-
NPs@5PEI following the same protocol as previously described for the GFP plasmid. Those 
plasmid-loaded nanoparticles were incubated with DMSCs for 2 h and non-internalized 
nanoparticles were removed by washing with PBS. Seventy two hours later, 5-FC was added 
to DMSCs and the viability of DMSCs was evaluated after further incubation for 5 days (Figure 
4). Bright field microscopy showed a reduction in cell culture density of transfected DMSCs 
treated with 5-FC compared to control, while no significant changes were observed with either 
pro-drug addition or transfection alone (Figure 4a). These results could indicate that the suicide 
genes are being expressed in DMSCs and the production of toxic species upon the addition of 
the pro-drug is hampering cell proliferation. Furthermore, apoptotic nuclei evidenced by 
brighter DAPI staining were observed by fluorescence microscopy in the transfected DMSCs 
exposed to the pro-drug (Figure 4b), as would be expected from the production of the highly 
toxic 5-FUMP. DMSCs exposed to those treatments were also evaluated by flow cytometry 
with an apoptosis-necrosis assay (Figure 4c). In each panel, cells in the lower left quadrant 
correspond to healthy cells, lower right quadrant are early-apoptotic cells, and upper-right 
quadrant comprises late-apoptotic or necrotic cells. An increase in late apoptotic/necrotic cells 
was observed only in the transfected DMSCs exposed to 5-FC.  
Gene expression evaluated by RT-PCR confirmed the production of mRNA corresponding to 
the introduced sequence in DMSCs treated with a plasmid-bearing UR-NPs@5PEI (Figure 
S3a). The expression of the housekeeping β-actin gene was also evaluated. CD:UPRT 
expression was found in transfected DMSCs corresponding to three independent experiments. 
No CD:UPRT expression was found in control no-transfected DMSCs whereas β-actin 
expression was detectable in all DMSCs cultures. These data confirm the successful and highly 




The activity of the CD:UPRT enzymes in cell lysates was also assessed in vial (Figure S3b).  
A significant conversion of the pro-drug was observed with lysates from transfected DMSCs, 
whereas no change in 5-FC concentration was observed with control DMSCs lysates. This 
transformation of the pro-drug 5-FC into other species demonstrates the expression of the 
enzymes in their active form. 
To sum up, all the above results confirm the successful transfection of DMSCs with the 
CD:UPRT plasmid, providing them the capability of converting non-toxic 5-FC into toxic 5-
FUMP, as shown in Scheme 1. This is especially interesting because the gene transfection 
process has been performed with a non-viral vector under conditions where DMSCs viability 
has not been affected (over 90% viable DMSCs after transfection). Once the vehicle cells have 
reached the tumor site they will produce the toxic species upon exposure to the pro-drug, which 
is completely devoid of toxicity in the absence of the activating enzyme (over 94 % viable 
DMSCs exposed to the pro-drug) (Figure 4c).  
One of the main advantages of the combination of CD and UPRT genes instead of using the 
CD gene alone is the increased bystander effect of 5-FUMP over 5-FU [23]. In order to test the 
bystander effect of our Trojan-horse platform, a Transwell co-culture with NMU mammary 
cancer cells was carried out [17,18]. CD:UPRT-transfected DMSCs were seeded on a 
Transwell cell culture insert that was placed in a well containing NMU cancer cells (1:2 ratio, 
DMSC:NMU). Seventy two hours after transfection of the DMSCs, the pro-drug 5-FC was 
added to the culture medium, and the viability of NMU cancer cells was evaluated 96 h later. 
Alamar Blue assay showed a significant decrease of NMU cell viability when exposed to our 
Trojan-horse platform in combination with 5-FC (Figure 5). These data indicate that transfected 
DMSCs produce a toxic drug when exposed to non-toxic 5-FC, which diffuses from the DMSC 
source, reaching the surrounding cancer cells and significantly affecting their growth. 




the number of early apoptotic NMU cells when employing our Trojan-horse therapeutic 
strategy compared to the other control conditions (Figure 6). 
In summary, the presented results confirm the successful preparation of a Trojan-horse 
platform capable of killing surrounding NMU cancer cells by nanoparticle-mediated genetic 
engineered DMSCs. The non-toxic nature of the pro-drug would ensure a good safety profile 
of the therapy, avoiding unnecessary exposure to a toxic molecule in healthy tissues and organs. 
Therefore, this anticancer therapeutic approach by the in situ production of a toxic molecule 
by tumor-tropic DMSCs transfected by non-viral nanovectors appears as a very promising tool 
for anticancer therapy. This effect could be additive to the previously demonstrated ultrasound-
triggered release of an anticancer drug from DMSCs-transported UR-NPs [17] and the inherent 
anticancer effect of DMSCs [8]. 
4. Conclusions 
The results obtained in this work demonstrate the possibility of inducing gene transfection 
using ultrasound-responsive mesoporous silica nanoparticles, without inducing significant 
toxicity to the vehicle cells (DMSCs), by employing a polyethylenimine coating of appropriate 
molecular weight. This developed non-viral transfection agent was used to transfect DMSCs 
with an expression plasmid containing two suicide genes, which provided them the capability 
of converting non-toxic 5-Fluorocytosine into toxic 5-Fluorouridine monophosphate. 
Moreover, DMSCs transfected with the suicide genes (Trojan-horse platform) are capable of 
inducing cell death in co-cultured NMU cancer cells, when exposed to the non-toxic pro-drug 
5-Fluorocytosine. 
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 Cell-mediated cancer therapy has recently attracted great interest. Tumor-homing 
cells can exert anticancer effects through innate capacities, via transfection with a 
therapeutic gene or acting as vehicles of therapeutic nanoparticles. In this work, an 
ultrasound-responsive mesoporous silica nanoparticle (capable of carrying an 
anticancer drug) is engineered to act as a non-viral transfection agent for tumor-tropic 
human placental mesenchymal stem cells. The successful transfection of the vehicle 
cells is evaluated employing different expression plasmids. After transfection with two 
suicide genes, the vehicle cells are capable of converting a non-toxic pro-drug into a 
highly toxic molecule, which can also kill surrounding cancer cells in an in vitro co-
culture model. This work opens the gate for a plethora of strategies in which both 
genes and drug-loaded nanoparticles can be transported towards tumor tissues by 
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